Nesher Technologies, Inc. (NTI) is at the forefront of nanobiotechnology, focusing on the development of advanced diagnostic and analytical systems. The company employs a proprietary single molecule detection (SMD) technology, specifically the Alternating Laser EXcitation (ALEX) method, which utilizes multi-color fluorescence spectroscopy. This innovative platform allows for the ultrasensitive and highly multiplexed detection of both protein and nucleic acid targets, enabling the simultaneous analysis of over 100 analytes from small patient samples. NTI's long-term vision includes creating fully automated, cost-effective in vitro diagnostic tests that can detect various diseases, including cancer, diabetes, and neurodegenerative disorders, at their earliest stages.

The ALEX technology not only enhances diagnostic capabilities but also provides critical insights into molecular interactions and dynamics, which are essential for understanding complex biological processes. This capability is particularly valuable in research and drug discovery, as it facilitates the study of gene transcription, protein maturation, and other vital mechanisms in both healthy and diseased states. NTI's commitment to advancing healthcare through innovative diagnostics is further supported by its collaborations and funding from the National Institutes of Health, which aim to develop next-generation tests for conditions such as Systemic Lupus Erythematosus and Alzheimer's Disease.

United States

Nesher Technologies is a biotechnology company specializing in nanobiotech for smarter diagnostics and cutting-edge biomedical research.

Nesher Technologies

Company Details